Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer

Inclusion Criteria: * Age ≥ 18 years * Histologically confirmed diagnosis of adenocarcinoma of the pancreas * Locally advanced (non-resectable) or metastatic pancreatic cancer * Presence of at least one uni-dimensional indicator lesion measurable by CT scan or MRI in not an irradiated area (RECIST criteria) * Immunohistochemical evidence or positive EGFR expression prior to study entry in primary tumor and/or at least one metastasis * Life expectancy of ≥ 3 months * Karnofsky performance status of ≥70 at study entry * Neutrophils ≥ 1.5 x 109/L, platelets ≥100 x 109/L, and hemoglobin ≥ 9 g/dL * Bilirubin level either normal or \< 1.5 x ULN * ASAT and ALAT ≤ 2.5 X ULN (≤ 5 x ULN if liver metastasis are present) * Serum creatinine \< 1.5 x ULN * Effective contraception for both, male and female patients if the risk of conception exists * Signed written informed consents prior to beginning protocol specific procedures Exclusion Criteria: * Brain metastasis * Previous chemotherapy for locally advanced or metastatic pancreatic cancer * Adjuvant therapy is allowed if recurrence is documented \> 6 months after the end of adjuvant treatment * Radiotherapy within 4 weeks prior to study entry * Concurrent chronic systemic immune therapy * Any investigational agent(s) 4 weeks prior to entry * Previous exposure to EGF, monoclonal antibodies, signal transduction inhibitors or EGFR targeting therapy * Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months * Known grade 3 or 4 allergic reaction to any of the components of the treatment * Known drug abuse/ alcohol abuse * Legal incapacity or limited legal capacity * Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent * Women who are pregnant or breastfeeding * Any concurrent malignancy other than non-melanoma skin cancer, or carcinoma in situ of the cervix. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial).